The role of the immune system in the physiopathology of osteoporosis

Valentina Cagnetta
Vittorio Patella

Department of Clinical Methodology
and Surgical Techniques, Orthopedics Section II,
University of Bari "Aldo Moro", Bari, Italy

Address for correspondence:
Valentina Cagnetta, MD
Department of Clinical Methodology and
Surgical Techniques, Orthopedics Section II
University of Bari "Aldo Moro"
Piazza Giulio Cesare, 11
70100 Bari, Italy
Phone/Fax: +39 080 5592719
E-mail: valentinaca@hotmail.it

Summary

The close anatomical relationship between the immune system, estrogen deficiency and bone loss has been recognized for centuries but the existence of a functional relationship has emerged only recently. The role of the immune system in the development of senile osteoporosis, which arises primarily through the effects of estrogen deficiency and secondary hyperparathyroidism, is slowly being unraveled. This review focuses the evidence that links immune cells, inflammation, cytokine production and osteoclast formation and their activity. The under standing of the interplay of inflammation and osteoclast can lead to the development of new drugs for prevention and treatment of bone loss.

KEY WORDS: osteoporosis; immune system; osteoclast; cytokines; T cells; B cells.

Introduction

Bone provides structural integrity for the body, it is the site of hematopoiesis and it is a storehouse for calcium and phosporus (1). Likewise, the immune system provides organism with protection from invading pathogens (2). Multiple overlapping and interacting mechanisms have envolved to regulate both systems. The osteoblasts are critical regulator of the hematopoietic stem cell niche from which all blood and immune cell derive, the osteoclast appear to share a common origin with the myeloid precursor cells that also gives rise to macrophages and myeloid dendritic cells. Multiple soluble mediators of immune cell function including cytokine, chemochines and growth factor also regulate osteoblast and osteoclast activity (3). Inflammatory disease characterized by systemic and local bone loss is an interesting field with which to explore the relationship between activation of the immune system and bone remodelling. Estrogen deprivation induces bone loss. At the same time estrogens are well known regulators of the immune system and T cell functions (4, 5). Thus the immune system can be suggested as a key interface between estrogen deprivation and bone metabolism. This review aims to summarize the evidences linking immune activation and bone loss with particular attention to humans.

Estrogen loss and immune system

The immune system plays a critical role in the pathophysiology of postmenopausal osteoporosis. Estrogen deficiency induces bone loss and at the same time estrogen mild increase in production of proinflammatory cytokines, such as IL-1, IL-6, and TNF-alpha, systemically and locally, which promotes osteoclastogenesis in the bone marrow because they are well known regulators of the immune system and T cell function (6). The most important cytokine in the context of estrogen deficiency-induced bone loss has been shown to be TNFα produced by bone marrow T-lymphocytes that are stimulated through a complex mechanism involving antigen-presenting cells and various cytokines including IL-7, IFN-gamma, and TGF-beta. Proinflammatory cytokines also suppress osteoblastogenesis, while the crosstalk between T-lymphocytes and marrow stromal cells regulates the osteoclastogenic activity of the latter. Estrogen plays a fundamental role in skeleton growth and bone omeostasis and the role of estrogen in the regulation of immune function has been demonstrated in animals and humans: immune cells are more responsive to antigenic stimulus in hormone replacement therapy users than non-users (7).

D'Amelio et al. demonstrated that T cells from post- menopausal women show blunt reaction to immune stimulation in respect to pre-menopausal healthy women. At baseline, T cells are more active than in healthy post- and pre-menopausal controls: this implies their greater ability to produce RANKL and TNF-alpha, thus inducing OC formation and activity (8). They have also demonstrated that OC formation is abolished in T cell-depleted PBMC cultures and this phenomenon is reversed only by the addition of M-CSF and RANKL in cultures.

Estrogen withdrawal up-regulates TNF-alpha production by T cells through a complex pathway involving the thymus and bone marrow. In the bone marrow, ovariectomy promotes T cell activation by increasing antigen presentation by macrophages and DCs (9, 10). The relevance of TNF in the mechanism by which estrogen causes bone loss has been demonstrated using multiple animal model. For example in the murine model ovariectomy increases the number of bone marrow T cell-producing TNF (11-13). The effects of ovx on antigen presentation and the resulting changes in T-cell activation, proliferation, and lifespan are explained by a stimulatory effect of ovx on the expression of the gene-encoding class II transactivator (CIITA). The product of the CIITA gene is a non-DNA binding factor that functions as a transcriptional co-activator, when recruited to the MHCII promoter by interaction with promoter-bound factors (14). CIITA expression is required and sufficient for the stimulation of antigen presentation in bone marrow monocytes with the final effect of up-regulation of expression of MHCII on macrophages (9, 15, 16). This process proved essential since data show that ovariectomy induces rapid bone loss in wild type mice but failed to do so in TNFα-deficient [TNFalpha (-/-)] mice and in T cell-deficient nude mice.

Moreover, RANKL-expression on lymphocytes and marrow stromal cells is significantly elevated during estrogen deficiency in humans and correlates directly with increases in bone resorption markers and inversely with serum estrogen levels (17).

Estrogen withdrawal has effects on the B cell compartment. B cells have recently been directly implicated in the regulation of bone resorption as they represent a major source of OPG. Historically, an extensive *in vitro* data set has led to the widely accepted precept the mayor source of BM OPG is the OB and/or its immediate precursor, the BM SC. More recent data have show that B cell are more likely the dominant producers of OPG in the bone microenvironment *in vivo* (18). This conclusion was arrived at following an extensive series of investigations into the bone phenotype of B cell Knockout (KO) mice (18). B cell KO mice present at baseline with an osteoporotic phenotype (19), a consequence of enhanced osteoclastic bone resorption. Examination of the RANKL/OPG ratio B cell KO bone marrow identified a specific deficiency in OPG mRNA and in the protein expression (18). Reconstitution of young B cell KO mice with B cell by means of adoptive transfer, completely rescued mice from development of osteoporosis, by normalizing OPG production (18). B cells play an important role in regulating basal OC formation and in regulating bone omeostasis.

Cytokines and OC formation

OCs arise by citokine-driven proliferation and differentiation of monocyte precursors that circulate within the hematopoietic cell pool. The minimal essential cytokines required for OC formation under basal conditions are RANKL and M-CSF. The Receptor Activator of NFkB Ligand (RANKL) and Macrophage Colony Stimulating Factor (M-CSF) are produced by bone marrow stromal cells (20), OBs (21) and activated T cells (2, 22). The co-stimulation by RANKL and M-CSF is essential for the differentiation of monocytes into OCs (23, 24).

M-CSF induces the proliferation of OC precursors, differentiation and fusion of more mature OCs and increases the survival of mature OCs. RANKL promotes the differentiation of OC precursors into fully mature multinucleated OCs and stimulates the capacity of mature OCs to resorb bone.

RANKL is a member of the TNF superfamily, present both as a transmembrane and in secreted form. It binds to its physiological receptor RANK expressed on the surface of OC lineage cells. Its action is opposed by osteoprotegerin (OPG), a neutralizing soluble decoy receptor, produced by marrow stromal cells and OBs (23). Estrogen deficiency induces the imbalance between RANKL and OPG; this phenomenon is important in the genesis of post-menopausal bone loss (24, 25).

Some studies questioned the central role of RANKL. *In vivo* RANKL-deficient mice have significant osteopetrosis and no osteoclasts, but a normal number of monocyte/macrophages (26). These mice also exhibit failed tooth eruption, which is a common defect associated with developmental osteopetrosis, and diversion of hematopoiesis to the spleen and liver because a functional bone marrow cavity fails to form in the absence of osteoclasts (26, 27). Marrow stromal and osteoblastic cells produce RANKL, and regulation of its mRNA expression in murine marrow cell cultures correlates with activation of osteoclastogenesis (28).

RANK-deficient mice were demonstrated to phenocopy the defect in osteoclast development that was observed in the RANKL-knockout mouse, confirming the exclusive specificity of RANKL for osteoclast-expressed RANK (29).

Estrogen deficiency induces bone loss through a complex modification of cytokine production balance. Primarily, researchers observed increased TNFalpha production by T cells both in ovariectomized mice (11) and post- menopausal women (2, 30). TNFalpha enhances OC formation by up-regulating stromal cell pro-

duction of RANKL and M-CSF and by increasing the responsiveness of OC precursors to RANKL (6, 31).

Like TNF, interleukin (IL)-1 promotes RANKL expression by bone marrow stromal cells and OBs and stimulates OC lifespan and activity. IL-1 directly targets OC precursors and promotes OC differentiation in the presence of permissive levels of RANKL. Recent evidence has also shown that IL-1 mediates, in part, the osteoclastogenic effect of TNF and does so by enhancing stromal cell expression of RANKL and by directly stimulating differentiation of OC precursors (32). TNF and IL-1 engage initially distinct signaling pathway that converge with the activation of the transcription factor NF-*k*B and the stimulation of the miogeno-activated protein kinase (MAPK) system. Thus, the combined effect of these two cytokines provides a potent signal to osteoclastogenesis, inhibition of OB function, and regulation of the lifespan of skeletal cells.

An important yet controversial OC regulating factor is interferon (IFN)-gamma. This cytokine has an anti osteoclastogenic effect *in vitro* (33) and *in vivo* in nude mice models (34, 35). Studies in humans indicate an increased level of IFNgamma during estrogen deficiency (36, 39), in leprosy and rheumatoid arthritis with bone erosions (37, 38). Moreover, data from randomized controlled trials have shown that IFNgamma does not prevent bone loss in patients with RA (39, 40) nor the bone wasting effect of cyclosporin A (41). These data are explained by the finding that IFNgamma influences OC formation both via direct and indirect effects (36). It directly blocks OC formation targeting maturing OC (42) and also induces antigen presentation and thus T cell activation. When IFNgamma levels are increased in vivo, activated T cells secrete pro-osteoclastogenic factors and this activity off- sets the anti-osteoclastogenic effect of IFNgamma (43).

Another cytokine relevant for OC formation is interleukin-7 (IL-7). Some studies have demonstrated that IL-7 promotes osteoclastogenesis by up-regulating T cell-derived osteoclastogenic cytokines including RANKL (44, 45) and that the production is up-regulated by estrogen deficiency. *In vivo* IL-7 blockade is proven to suppress T cell expansion and TNFalpha and IFNgamma production, preventing bone loss due to estrogen deprivation (46, 47). In healthy humans, the expression of IL-7 receptors on T lymphocytes is strictly related to their ability to induce OC formation from peripheral blood mononuclear cells (48).

Osteoporosis and inflammation

Several inflammatory diseases such as rheumatoid arthritis, sistemic lupus erythematosus, inflammatory bowel disease, celiac disease, cystic fibrosis and chronic obstructive pulmonary disease have been associated to bone resorption. The link between osteoclast, macrophage colony stimulating factor and pro-inflammatory cytokines, especially TNFalpha and IL-1 explain the association between inflammation and osteoporosis. The activation of T cells in autoimmunity or during infection increases RANKL production and promote osteoclastogenesis. The process can be reverted by the administration of OPG in several pathological conditions such as RA and periodontitis (49). Particularly in autoimmune arthritis, T cell subsets have been examined and Th17 cells, a specialized inflammatory subset, have been identified as responsible for osteoclastogenesis regulation. An inflammatory milieu induces naive T cells to differentiate into Th17, capable to produce RANKL, TNFalpha and IL-17, a cytokine that increases RANKL expression by OBs (50).

Researchers recently began to investigate a possible direct role of dendritic cells (DC) in inflammation related bone damage. DCs are known for their role of antigen presenting cells (APCs) and do not appear to play a role in bone homeostasis in non-pathological conditions, but some data suggest that DC could act as OC precursors in an inflammatory milieu, transforming into DC-derived-OC according to phenotypic and functional characterization

studies. Moreover, DCs modulate T cell activity through RANK/RANKL pathway and other cytokines associated with osteoclastogenesis (51-53). There is a lack of definitive evidence about the physiological relevance of this phenomenon *in vivo* but DCs could act as an osteo-immune interface, contributing to bone loss in inflammatory diseases.

On the other hand investigators have focused on the role of B-lymphocytes in periodontal inflammation. The host immune response is partly responsible for the bone destruction in cases of periodontitis and the RANK/ RANK/OPG signalling axis is important both in bone and immune system communication. Data suggest that B-lymphocyte involvement in the adaptive immune re- sponse contributes to bone resorption by up-regulating of RANKL expression through Toll-like receptor path- ways. These data align with the known ability of T cells to produce RANKL in the presence of immune stimulus and to increase osteoclastogenesis (54).

Other studies focused on psoriatic arthritis, a chronic inflammatory disease characterized by joint erosions mediated by OCs. These OCs seem to derive from CD14+CD16+ circulating monocytes, present at higher level in patients than in healthy controls when exposed to OC-promoting microenvironment (M-CSF and RANKL). OCs do not derive from this population in healthy controls; thus CD16 can be considered a marker of OC precursors in arthritis (55).

Conclusion

Remarkable progress has been made using animal models to elucidate the cellular and molecular mechanisms governing homeostasis, the cross-talk between the immune system and bone leading to bone loss due to dysregulation of T lymphocyte function.

If these relationships are equally relevant in humans as they are in rodents, osteoporosis may soon become classified as an inflammatory or autoimmune condition and postmenopausal osteoporosis should be regarded as an inflammatory disorder sustained by a chronic mild decrease in T cell tolerance. And if these discoveries can be translated into humans, a door will be opened to exciting new potential therapeutic agents and strategies that target the bone-immune interface to ameliorate bone disease in numerous osteoporotic conditions. However, despite extensive cross-regulation between bone metabolism and the immune system, a number of questions remain, such as the mechanisms by which these systems cross-regulate. The fresh insights gained from osteoimmunology will eventually lead to targeted therapies for diseases that affect either or both systems.

References

1. Raisz LG, Kream BE, Lorenzo JA, et al. Metabolic bone disease 2002. In: Davies TF, Larsen PR, Kronenberg HM, eds. Williams textbook of endocrinology. Philadelphia: W.B. Saunders; 1373.
2. Rosenberg HF, Gallin JI, Paul WE. Inflammation 1999. In: Paul WE, ed. Fundamental immunology. Philadelphia: Lippincott-Raven; 1051.
3. Horowitz MC, Lorenzo J. Local regulators of bone: IL-1, TNF, and lymphotoxin, interferon gamma, IL-8, IL-10, IL-4, the LIF/IL-6 family and additional cytokines. Principals of bone biology J. Academic Press. San Diego, California, USA. 1996;961-977.
4. Weitzmann MN, Pacifici R. T cells: unexpected players in the bone loss induced by estrogen deficiency and in basal bone homeostasis. Ann N Y Acad Sci 2007;1116:360-375.
5. Straub RH. The complex role of estrogens in inflammation. Endocr Rev 2007;28:521-574.
6. Roato I, Brunetti G, Gorassini E, et al. IL-7 up-regulates TNF-alpha-dependent osteoclastogenesis in patients affected by solid tumor. PLoS One 2006;1: e124.
7. Porter VR, Greendale GA, Schocken M, et al. Immune effects of hor-
8. D'Amelio P, Grimaldi A, Di Bella S, et al. Estrogen deficiency increases osteoclastogenesis up- regulating T cells activity: a key mechanism in osteoporosis. Bone 2008;43:92-100.
9. Cenci S, Toraldo G, Weitzmann MN, et al. Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-gamma-induced class II transactivator. Proc Natl Acad Sci USA 2003;100:10405-10410.
10. Adamski J, Ma Z, Nozell S, Benveniste EN. 17 beta-Estradiol inhibits class II major histocompatibility complex (MHC) expression: influence on histone modifications and cbp recruitment to the class II MHC promoter. Mol Endocrinol 2004;18:1963-1974.
11. Roggia C, Gao Y, Cenci S, et al. Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc Natl Acad Sci USA 2001;98:13960-13965.
12. Gao Y, Qian WP, Dark K, et al. Estrogen prevents bone loss through transforming growth factor beta signaling in T cells. Proc Natl Acad Sci USA 2004;101:16618-16623.
13. Roggia C, Tamone C, Cenci S, et al. Role of TNF-alpha producing T-cells in bone loss induced by estrogen deficiency. Minerva Med 2004;95:125-132.
14. Boss JM, Jensen PE. Transcriptional regulation of the MHC class II antigen presentation pathway. Curr Opin Immunol 2003;15:105-111.
15. Kim JH, Kim K, Youn BU, et al. MHC class II transactivator negatively regulates RANKL-mediated osteoclast differentiation by down-regulating NFATc1 and OS-CAR. Cell Signal 2010;22:1341-1349.
16. Mueller RB, Skapenko A, Grunke M, et al. Regulation of myeloid cell function and major histocompatibility complex class II expression by tumor necrosis factor. Arthritis Rheum 2005;52:451-460.
17. Eghbali-Fatourechi G, Khosla S, Sanyal A, et al. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 2003;111:1221-1230.
18. Nagarajan UM, Bushey A, Boss JM. Modulation of gene expression by the MHC class transactivator. J Immunol 2002;169:5078-5088.
19. Li Y, Toraldo G, Li A, et al. B cell and T cell are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood 2007; 109: 3839-3848.
20. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001;142:5050-5055.
21. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998;95:3597-3602.
22. Horwood NJ, Kartsogiannis V, Quinn JM, et al. Activated T lymphocytes support osteoclast formation in vitro. Biochem Biophys Res Commun 1999;265:144-150.
23. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-323.
24. Hofbauer LC, Khosla S, Dunstan CR, et al. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000;15:2-12.
25. Eghbali-Fatourechi G, Khosla S, Sanyal A, et al. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 2003;111:1221-1230.
26. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-323.
27. Kim N, Odgren PR, Kim DK, et al. Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene. Proc Natl Acad Sci USA 2000;97:10905-10910.
28. Lee SK, Lorenzo JA. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology 1999;140:3552-3561.
29. Dougall WC, Glaccum M, Charrier K, et al. RANK is essential for osteoclast and lymphnode development. Genes Dev 1999;13:2412-2424.

mone replacement therapy in post- menopausal women. Exp Gerontol 2001; 36:311-326.

30. Pacifici R, Brown C, Puscheck E, et al. Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc Natl Acad Sci USA 1991;88:5134-5138.

31. Hotokezaka H, Sakai E, Ohara N, et al. Molecular analysis of RANKL-independent cell fusion of osteoclast-like cells induced by TNF-alpha, lipopolysaccharide, or peptidoglycan. J Cell Biochem 2007;101:122-134.

32. Wei S, Kitaura H, Zhou P, et al. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 2005;115:282-290.

33. Takayanagi H, Ogasawara K, Hida S, et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 2000;408:600-605.

34. Sato K, Satoh T, Shizume K, et al. Prolonged decrease of serum calcium concentration by murine gamma-interferon in hypercalcemic, human tumor (EC-GI)bearing nude mice. Cancer Res 1992;52:444-449.

35. Tohkin M, Kakudo S, Kasai H, et al. Comparative study of inhibitory effects by murine interferon gamma and a new bisphosphonate (alendronate) in hypercalcemic, nude mice bearing human tumor (LJC-1-JCK). Cancer Immunol Immunother 1994;39:155-160.

36. Gao Y, Grassi F, Ryan MR, et al. IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J Clin Invest 2007;117:122-132.

37. Arnoldi J, Gerdes J, Flad HD. Immunohistologic assessment of cytokine production of infiltrating cells in various forms of leprosy. Am J Pathol 1990;137:749-753.

38. Firestein GS, Alvaro-Gracia JM, Maki R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol 1990;144:3347-3353.

39. Cannon GW, Pincus SH, Emkey RD, et al. Double-blind trial of recombinant gamma-interferon versus placebo in the treatment of rheumatoid arthritis. Arthritis Rheum 1989;32:964-973.

40. Veys EM, Menkes CJ, Emery P. A randomized, double-blind study comparing twenty-four-week treatment with recombinant interferon-gamma versus placebo in the treatment of rheumatoid arthritis. Arthritis Rheum 1997;40:62-68.

41. Mann GN, Jacobs TW, Buchinsky FJ, et al. Interferon-gamma causes loss of bone volume in vivo and fails to ameliorate cyclosporin A-induced osteopenia. Endocrinology 1994;135:1077-1083.

42. Takayanagi H, Kim S, Taniguchi T. Signaling crosstalk between RANKL and interferons in osteoclast differentiation. Arthritis Res 2002; 4 Suppl 3:S227-S232.

43. Pacifici R. Estrogen deficiency, T cells and bone loss. Cell Immunol 2008;252:68-80.

44. Toraldo G, Roggia C, Qian WP, et al. IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. Proc Natl Acad Sci USA 2003;100:125-130.

45. Weitzmann MN, Roggia C, Toraldo G, et al. Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency. J Clin Invest 2002;110:1643-1650.

46. D'Amelio P, Grimaldi A, Bernabei P, et al. Immune system and bone metabolism: Does thymectomy influence post menopausal bone loss in human? Bone 2006;39:658-665.

47. Ryan MR, Shepherd R, Leavey JK, et al. An IL-7-dependent rebound in thymic T cell output contributes to the bone loss induced by estrogen deficiency. Proc Natl Acad Sci USA 2005;102:16735-16740.

48. Gendron S, Boisvert M, Chetoui N, Aoudjit F. Alpha1beta1 integrin and interleukin-7 receptor up-regulate the expression of RANKL in human T cells and enhance their osteo- clastogenic function. Immunology 2008;125:359-369.

49. Kong YY, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999;402:304-309.

50. Sato K, Suematsu A, Okamoto K, et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006;203:2673-2682.

51. Cutler CW, Teng YT. Oral mucosal dendritic cells and peri- odontitis: many sides of the same coin with new twists. Periodontol 2000 2007;45:35-50.

52. Alnaeeli M, Park J, Mahamed D, et al. Dendritic cells at the osteoimmune interface: implications for inflammation induced bone loss. J Bone Miner Res 2007;22:775-780.

53. Alnaeeli M, Teng YT. Dendritic cells: a new player in osteoimmunology. Curr Mol Med 2009;9:893-910.

54. Han X, Lin X, Seliger AR, et al. Expression of receptor activator of nuclear factor-kappaB ligand by B cells in response to oral bacteria. Oral Microbiol Immunol 2009;24:190-196.

55. Chiu YG, Shao T, Feng C, et al. CD16 (FcRgammaIII) as a potential marker of osteoclast precursors in psoriatic arthritis. Arthritis Res Ther 2010;12: R14.